BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7846351)

  • 1. [A randomized study of navelbine compared to navelbine and cisplatin compared to vindesine and cisplatin in the treatment of inoperable non-small-cell lung carcinoma. The results of a European multicenter study including 612 patients].
    González Larriba JL; Alberola V; Lianes P; Panizo A; Carrato A; Muñoz Quintana A; Cardenal F; Gracia JM; Moyano A; Díaz-Rubio E
    Rev Clin Esp; 1994 Nov; 194(11):953-9. PubMed ID: 7846351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
    Le Chevalier T; Brisgand D; Pujol JL; Douillard JY; Monnier A; Rivière A; Chomy P; Le Groumellec A; Ruffie P; Gottfried M; Gaspard MH; Chevreau C; Alberola V; Cigolari S; Besson F; Martinez A; Besenval M; Berthaud P; Tursz T
    Bull Cancer; 1996 May; 83(5):385-94. PubMed ID: 8680091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
    Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
    Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
    J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study.
    Elliott JA; Ahmedzai S; Hole D; Dorward AJ; Stevenson RD; Kaye SB; Banham SW; Stack BH; Calman KC
    Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1025-32. PubMed ID: 6540685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of three regimens using vinorelbine (Navelbine) for non-small cell lung cancer.
    Hillner BE; Smith TJ
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):25-30. PubMed ID: 8610234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update: vinorelbine (navelbine) in non-small cell lung cancer.
    Crawford J
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):2-7. PubMed ID: 8610232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
    Soria JC; Brisgand D; Le Chevalier T
    Ann Oncol; 2001 Dec; 12(12):1667-70. PubMed ID: 11843242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.
    Le Chevalier T; Brisgand D; Soria JC; Douillard JY; Pujol JL; Ruffie P; Aberola V; Cigolari S
    Oncologist; 2001; 6 Suppl 1():8-11. PubMed ID: 11181998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A late phase-II trial comparing KW-2307 with vindesine in non-small cell lung cancer (1). Lung cancer section in KW-2307 Study Group].
    Furuse K; Yamori S; Negoro S; Fukuoka M; Takada Y; Nakai Y; Ikegami H; Fujii M; Nakajima S; Katakami N
    Gan To Kagaku Ryoho; 1995 Jan; 22(1):67-76. PubMed ID: 7826080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
    Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
    Coltman CA
    Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Navelbine (vinorelbine): a review of its antitumor activity and toxicity in clinical studies].
    Niitani H
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1495-507. PubMed ID: 10500542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: a randomized trial comparing two dosages of cisplatin.
    Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tominaga K; Sakurai M; Suga J; Miyaoka H; Sano T; Keicho N
    Jpn J Cancer Res; 1986 Aug; 77(8):782-9. PubMed ID: 3019976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.
    Smith TJ; Hillner BE; Neighbors DM; McSorley PA; Le Chevalier T
    J Clin Oncol; 1995 Sep; 13(9):2166-73. PubMed ID: 7666075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Rixe O; Gatineau M; Jauffret E; Spano JP; Orcel B; Vannetzel JM; Berille J; Derenne JP; Khayat D
    Bull Cancer; 2005 Jan; 92(1):E1-6. PubMed ID: 15689321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
    Luedke DW; Einhorn L; Omura GA; Sarma PR; Bartolucci AA; Birch R; Greco FA
    J Clin Oncol; 1990 May; 8(5):886-91. PubMed ID: 2159054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer.
    Shinkai T; Eguchi K; Sasaki Y; Tamura T; Ohe Y; Kojima A; Oshita F; Saijo N
    Eur J Cancer; 1991; 27(5):571-5. PubMed ID: 1647183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.